Fresenius Medical Care AG
FMSHealthcareNASDAQMedical Care Facilities · Last scanned Oct 26, 2026
Scan Results
Daily timeframeFresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. At a $12.07B market cap, Fresenius Medical Care AG ranks as a large-cap company within healthcare. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Market Cap
$12.07B
Beta
0.81
P/E (TTM)
11.69
P/E (Fwd)
7.62
EPS (TTM)
$1.94
EPS (Fwd)
$2.98
ROE
8.5%
ROA
4.0%
Cash
$1.06B
Total Debt
$10.98B
Free CF
$2.02B
52W Change
-16.6%
Annual Financials
Cash vs Debt
Where FMS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, FMS finished 2.75% below its 150-day moving average ($22.56) and 2.40% below its 200-day moving average ($22.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FMS overbought or oversold?
At the October 20, 2026 close, FMS's RSI(14) was 46.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, FMS has $1.06B in cash with $10.98B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $2.02B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 8.5%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $17.62B to $19.63B.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FMS.